Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comments on the appraisal consultation
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from Eisai/Pfizer
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from Lundbeck
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the executable model from Lundbeck
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from Novartis
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from Shire
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from Alzheimer's Society
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from Association of British Neurologists
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from British Geriatrics Society
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from Royal College of Nursing
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from Royal College of Psychiatrists
This page was last updated: 03 March 2011